Application Nr Approved Date Route Status External Links
ANDA211292 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Frovatriptan Succinate Tablets Are Indicated For The Acute Treatment Of Migraine With Or Without Aura In Adults. Limitations Of Use Use Only If A Clear Diagnosis Of Migraine Has Been Established. If A Patient Has No Response For The First Migraine Attack Treated With Frovatriptan Succinate Tablets, Reconsider The Diagnosis Of Migraine Before Frovatriptan Succinate Tablets Are Administered To Treat Any Subsequent Attacks. Frovatriptan Succinate Tablets Are Not Indicated For The Prevention Of Migraine Attacks. Safety And Effectiveness Of Frovatriptan Succinate Tablets Have Not Been Established For Cluster Headache. Frovatriptan Succinate Is A Serotonin (5-Ht 1b / 1d ) Receptor Agonist (Triptan) Indicated For The Acute Treatment Of Migraine With Or Without Aura In Adults. ( 1 ) Limitations Of Use Use Only After A Clear Diagnosis Of Migraine Has Been Established. ( 1 ) Not Indicated For The Prophylactic Therapy Of Migraine. ( 1 ) Not Indicated For The Treatment Of Cluster Headache. ( 1 )

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Frovatriptan Succinate FROVATRIPTAN SUCCINATE ZINC895030

Comments